Purpose Hematopoietic cell transplantation (HCT) provides a curative therapy for severe forms of primary immunodeficiencies (PID). While the timing and extent of Tcell reconstitution following transplant for PID has been studied in depth, less is known about the kinetics of B-cell development and long-term restoration of humoral functions, which been often reported to be suboptimal after HCT. Methods We studied longitudinally B-cell development and function in a cohort of 13 PID patients transplanted between 1997 and 2010, with a follow-up ranging from 0.7 to 15 years. Flow cytometric analysis of naïve and antigen-experienced Bcell subsets and in vitro functional responses to CpG were compared with data from healthy children and correlated with the degree of B-cell chimerism and in vivo antibody production.
Results
We found that total memory B-cells count remained below normal levels for the first 2 years of follow up and progressively normalized. Switched memory B-cells (CD19+ CD27+IgD-IgM-) were restored early and better than IgM memory B-cells (CD19+CD27+IgD+IgM+), which remained significantly reduced long-term. The recovery of memory Bcells correlated with good in vivo humoral function and normalization of CpG-response. A complete B-cell reconstitution was usually associated with donor B-cells chimerism and pretransplant conditioning. Donor source and the underlying genetic defect represented also important variables. Conclusion Monitoring of phenotypic and functional changes on B-cells following HCT may prove clinically relevant to tailor patients' care. In particular the analysis of IgM memory and switched memory B-cells in addition to in vitro B-cells stimulation are recommended before Ig replacement therapy (IgRT) discontinuation.
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Introduction
Hematopoietic cell transplantation (HCT) provides a curative therapy for primary immunodeficiencies (PID), a heterogeneous group of inherited disorders affecting the immune system and leading to recurrent severe infections and predisposition to autoimmunity and cancer [1] [2] [3] . The outcome of HCT has improved considerably due to better supportive care, graft versus host disease (GVHD) prevention and use of the reduced intensity conditioning regimen and novel strategies for stem cell manipulation and purification [4] [5] [6] [7] [8] . While the timing and extent of T-cell reconstitution has been studied in depth [9] [10] [11] [12] [13] [14] , less is known about B-cell development and functions after transplant for PID. Previous studies suggested that B-cell recovery can be slower than T-cell reconstitution and often suboptimal, and in these patients immunoglobulin replacement therapy (IgRT) is still required [15] [16] [17] [18] . It has been suggested that delayed or partial humoral reconstitution is often associated to the persistence of autologous defective B lymphocyte [19] [20] [21] . The use of myeloablative conditioning facilitates establishment of donor B lymphocyte chimerism [22] [23] [24] , but this benefit may be outweighed by the increased toxicity and some patients may require IgRT even after pretransplantation conditioning [25, 26] . Moreover, humoral reconstitution is also influenced by the molecular type of PID, degree of HLA compatibility, source of grafts, and posttransplant course (e.g. infections and GVHD) [25, [27] [28] [29] .
Here, we studied long-term B-cell reconstitution in a small cohort of PID patients who received different sources of HCT. We found that the kinetic of recovery of naïve and antigenexperienced B cells was variable and mainly influenced by the degree of donor chimerism, type of donor source and the underlying disease. Our data suggest that monitoring of phenotypic and functional changes on B-cells following HCT may allow to identify early predictors of efficient humoral function.
Methods

Patients' Characteristics and Data Collection
We collected data on immune reconstitution and clinical status after HCT of 16 patients who consecutively underwent HCT at Bambino Gesù Children's Hospital (OPBG) in Rome between 2002 and 2010 and one patient who was transplanted in 1997 at the Necker-Enfants Malades Hospital and followed at OPBG. Data on immune reconstitution and clinical status after HCT were collected until the end of 2012. PID was diagnosed based on clinical findings, immune phenotype and function, and confirmed by genetic analysis. In 2 patients no mutations were identified. In vivo T cell depletion has been used in 12 procedures (all but one mismatched related donor -MMRD-, all matched unrelated donor-MUD-and two matched sibling donor -MSD-transplants) by antithymocyte globulin or Alemtuzumab or anti-CD2 anti-leukocyte function atigen-1. In addition, Pt 11 received a donor graft enriched for CD34+ cells. Patients underwent HCT from different donor sources (BM, n=14, CB, n=3), with (n=11) or without (n=6) conditioning treatment. The median age at transplantation was 11 months (range 5-144 months), patients' follow-up ranged from 0,7 to 15 years, with an overall survival of 77 %. Two SCID patients (Pt 2, 3) died early post HCT due to disseminated infections present at time of HCT, a patient affected by Wiskott-Aldrich syndrome (WAS) (Pt 13) died 9 months after HCT due to a EBV-positive diffuse large B-cell lymphoma, whereas one patient with Familial Haemophagocytic Lymphohistiocytosis (FHLH) (Pt 15) died 6 months after the rejection of the third HCT transplant (Table 1) . Patients' family signed informed consent for immunological studies under a research protocol approved by Ethic Committee of OPBG.
Chimerism and T Cell Function
Whole blood and sorted peripheral cell subsets (CD3+, CD19+, CD14+, CD16+56+) were studied for chimerism at 1, 3, and 6 months after HCT and then yearly. Chimerism was analyzed by fluorescence in situ hybridization for donor-recipient sex mismatches or by polymerase chain reaction amplification of short tandem repeats in case of donor-recipient sex-matching. Immunological reconstitution of T, B and NK populations were monitored by flow cytometry on peripheral blood mononuclear cells (PBMCs) according to standard protocols with a FACS CANTO II flow cytometer and monoclonal murine antibodies conjugated to FITC or PE specific for CD3, CD4, CD8, CD16, CD19, CD45RO, and CD45RA (30) . Pt17 was analyzed at 0.7 years before he returned to his country, and data were grouped with the 1 year follow up. The function of T lymphocytes was assessed by lymphocyte proliferation upon mitogens, T-cell repertoire and thymic activity (TREC) as previously described [30, 31] .
B Cell Function
Reconstitution of B-cell compartment was analyzed through multiple approaches including the analysis of naïve and antigen-experienced B-cell subsets (anti-CD27, anti-IgD and anti-IgM were used to identify different stages of B-cell maturation), the determination of immunoglobulin isotype, the IgG subclasses and the ability to generate antibodies to protein and polysaccharide antigens after tetanus toxoid, hepatitis B, Haemophilus influenzae and pneumococcal immunization. Bcell subsets references for controls were obtained from 81 healthy children at different age being referred to our hospital for elective procedures (14 children of 1 year, 7 of 2 years, 14 between 3 and 5 years, 46 between 6 and 15 years). We calculated the 5°and 95°percentile for each group of age and compared them to the values of patients according to the years following HCT. The ability of B-cells to differentiate, proliferate and produce immunoglobulins was tested by stimulation with bacterial DNA (CpG). Briefly, PBMC obtained through ficoll from peripheral blood of patients, were labeled at the f i n a l c o n c e n t r a t i o n o f 0 . 1 μ g / m l C M F D A ( 5 -chloromethylfluorescein diacetate, CellTracker; Molecular Probes) and cultured at 5×10 5 cells per well in 96-well plates in complete RPMI 1640 (InvivoGen) supplemented with 10 % FBS (HyClone Laboratories). Human CpG oligodeoxynucleotides (Hycult Biotechnology) was used at the optimal concentration of 2.5 μg/ml. Cell proliferation and differentiation into plasma cells, were measured on day 7 by FACSCanto II flow cytometer (BD Biosciences). Secreted Igs were detected at by ELISA [32] .
Results
Patients' Treatment and Donor Cell Engraftment
We studied longitudinally the immune reconstitution in 13 surviving PID patients in a cohort of 17 patients who received allogeneic HCT. Among them 6 patients had long-term follow-up (>5 years). Characteristics of patients and details about transplants are summarized in Table 1 . Conditioning regimens varied based on patient's underlying disease and clinical condition at transplantation. Successful hematopoietic engraftment was observed in all 13 survivors with a median time of 17 days (range 12-29 days) for neutrophils (ANC>500/ul) and 20 days (range 12-55 days) for platelets (>50,000/ul). Four patients developed grade II-III acute Graft versus Host Disease (GvHD), and one experienced chronic GvHD. In unconditioned SCID patients, nearly full donor chimerism was detected in the T-cell lineage whereas B-cell and monocytes remained mostly or totally of recipient origin. Specifically, 2 out of 4 non-conditioned patients had an absent donor B, monocyte and NK-cell engraftment (Fig. 1a) . In contrast, all patients who received cytoreductive conditioning regimens achieved stable full donor chimerism in all lineages, except one patient (Pt 8) with mixed chimerism on CD14+ cells. Three patients showed substantial fluctuations in donor Bcell contribution over time and in two of them an increase of donor B-cells occurred very late (>4 years) during follow up (Fig. 1b) . Interestingly, Pt5 (JAK-3 deficiency) and Pt6 (ADA-SCID) who received unconditioned transplants from siblings, showed normal humoral function despite the prevalence of host B-cells. When switched memory B-cells were sorted from these patients, molecular analyses of chimerism revealed that the majority of them were of donor origin (60 and 95 %, respectively, data not shown).
Effective Long-Term T-Cell Reconstitution T-cell immune reconstitution was evaluated at yearly follow up in 13 surviving patients. Complete T-cell count recovery was obtained in all except two patients who experienced severe clinical complications (GvHD, immune reconstitution syndrome associated to BCG). One year after HCT total CD3+, CD4+ and CD8+ cell counts were normal in the majority of patients. NK cell count was normal in all patient except one affected by γ-chain SCID and treated with HCT from unconditioned mismatched related donor. Evaluation of thymic function revealed normal CD4+CD45RA+ naïve Tcell counts and T-cell receptor excision circle (TREC) copies, in a high proportion of patients starting the first year after transplantation (Table 2 ) [33] . Of note, patients with reduced TREC values had received unconditioned transplants (data not shown). T-cell diversity analysis by T-cell repertoire spectratyping showed a polyclonal distribution in the CD4+ compartment and to a lower extent in CD8+ T-cells 12 months after transplantation, which was maintained or improved during follow up. T-cell proliferation in responses to both OKT3 and PHA achieved normal levels in 54 % of patients within 1 year after HCT. In 5 out of 6 long term-survivors (follow up >5 years) T-cell reconstitution was sustained over time. In Pt1 a decline in T cell count and functionality with skewed TCR profile, low response to PHA, undetectable TRECs, and appearance of face warts was observed 7 years after HCT.
B-Cell Development After HCT
One year after HCT proportions and absolute B-cell counts were significantly reduced as compared to age matched controls (Fig. 2a) ; they reached normal value for age after 2 years, remaining in the normal range long-term (>5 years). B-cell subsets were examined longitudinally in depth by multiparameter flow cytometry in 11 evaluable patients after transplant. We found a significant increase in the proportion of transitional B-cells (CD19+CD38++IgM++) at 1 year follow up, which normalized over time (Fig. 2b) . Total memory B-cells (CD19+ CD27+) were significantly below normal at 1 and 2 years and increased starting 3-5 years of follow up (Fig. 2c) . Remarkably, switched memory B-cells (CD19+CD27+IgD-IgM-) were restored earlier and better then IgM memory B-cells (CD19+CD27+IgD+IgM+), which remained significantly reduced in the long-term cohort (Fig. 2d, e) . B-cell absolute counts and percentage did not differ between MSD and MMRD transplant in long-term surviving patients, but the latter group displayed a reduced frequency of memory B-cells (data not shown).
In Vivo Antibody Production
The majority of patients discontinued IgRT between the first and second year after HCT and maintained normal values of IgG, IgA, IgM and IgG subclasses during the follow up [34] (Fig. 3) . Four patients required long-term IgRT substitution therapy. Pt1 (SCID γ-chain deficiency) did not attain donor B-cell engraftment whereas Pt11 (EDA-ID patient) was maintained on IgRT in spite of B-cell engraftment due to very low antibody response for S. pneumoniae antigens. Both patients showed very low frequency of memory B-cells and almost absent Fig. 1 Normal CD3+ cell count at different years post HCT: 1 year>1000/mcl, 2 years>1400/mcl, >5 years>1000/mcl; Normal CD4+ cell count at different years post HCT: 1 year>500/mcl, 2 years>650/mcl, >5 years>450/mcl; Normal CD8+ cell count at different years post HCT: 1 year>300/mcl, 2 years>400/mcl, >5 y>300/mcl; Normal CD4+CD45RA+cell count>200/mcl; Normal NK cell count >50 /mcl.Normal reference values according to (33) . Normal T cell function measured by proliferative response to mitogens (PHA>30.000 cpm and OKT3> 20.000 cpm, according to internal reference range)
switched B-cells for several years after HCT. Two other patients (Pt 7 and Pt 10) experienced severe clinical complications and required IgRT longer than 2 years after HCT. The nine patients in which IgRT was discontinued received vaccinations according to European Blood Marrow Transplantation (EBMT) recommendations [35] . Protective antibody titers developed following vaccination in almost all tested patients. One patient (Pt 4) required an additional hepatitis B booster three years after initial doses, one patient (Pt 14) required a fourth dose of conjugate pneumococcal vaccine and one patient (Pt 5) showed low titer anti-hepatitis B and anti-Pneumococcus 5 years after the last vaccinations. Isohemagglutinins appropriate for the blood group were found at significant titers in 7 patients evaluated beyond 1 year post HCT (Table 3 ).
In Vitro B-cell Functions After HCT
To better study restoration of B-cell functions in transplanted patients we studied B-cell proliferation, maturation and Ig production in vitro. B cells isolated from peripheral blood were stimulated with human CpG oligodeoxynucleotides (unmethylated bacterial DNA), an agonist of TLR9 expressed in human on plasmocitoid dendritic and B-cells and at high levels on memory Bcells [32, 36] . Under these conditions memory B-cells proliferate and differentiate to immunoglobulin-secreting cells in response to CpG through T-independent signalling. All 3 patients who underwent transplantation from a MSD showed an optimal and complete B-cell response.
In the MUD and MMRD cohort, B-cell proliferation, differentiation and antibody production were present in most patients but overall reduced as compared to MSD patients. In particular, 2 MMRD still requiring IgRT, failed to produce IgG and IgA in response to CpG (Table 4) .
Discussion
HCT is an established curative treatment for the most severe PID variants. However, reduced or poor humoral immune function can persist in a significant proportion of patients requiring lifelong IgRT and leading to a higher frequency of clinical complications such as infections, autoimmunity and chronic-GVHD [33, 37, 38] . In our cohort of long-term surving patients, the majority of patients were clinically well and did not experience severe late HCT-related complications.
In patients with long-term follow up (6-15 years) T-cell function was retained in all but one γ-chain patient who received a non-conditioned mismatched related HCT. In this case we observed a gradual decline of T-cell counts and functionality. Four patients experienced main clinical events including chronic GvHD requiring immunosuppressive therapy, chronic bronchopneumopathy, BCG reactivation, and warts. Of notice, all these patients required IgRT supplementation and 3 of them displayed low T-cell numbers and functions, indicating that long-term complications were associated with suboptimal immune reconstitution. We found that a good humoral function was usually associated with the presence of donor B-cell chimerism and promoted by myeloablative conditioning regimen. Indeed, all patients who received conditioning (n=9) showed a full donor B-cell chimerism and the majority (n=7; 78 %) discontinued IgRT 1-2 years after HCT maintaining protective levels of serum Igs and specific antibody titers (Table 5) .
Our data indicate that the development of the B-cell pool is a slow process after HCT for PID and that quantitative defects may persist in the long-term. The relative expansion of the transitional B-cell compartment in the first year after HCT is l (9/9) (7/7) (6/6) (9/9) (7/7) (6/6) (8 which occur even in presence of antibody production (41, 42) and remain relevant late complications after HCT. The establishment of the switched B-cell pool, generated in germinal center (GC)-dependent manner, reflects the T-cell reconstitution occurring from the first year post HCT and mirrors the ability to effectively respond to antigen and develop serological memory [44, 45] . Thus, a complete T-cell reconstitution is necessary for an appropriate B-cell function in the germinal center. Indeed, in the 9 patients who had discontinued IgRT and had a relevant specific antibody after vaccination, a progressive increase of both IgM and switched B-cell occurred and response to CpG normalized twelve months after HCT. In contrast, within the group of patients still requiring IgRT, two patients were severely lymphopenic (Pt7, Pt10) and two had No  5  2584  1139  1212  434  110  80  20  15  No  6  1396  613  629  160  238  75  35  75  No  7  155  109  43  36  166  >95  <5  <5  Yes  8  4190  2648  1033  607  798  >95  >95  75  No  9  2555  1480  810  730  314  >95  >95  >95  No  10  173  160  13  32  63  >95  >95  >95  Yes  11  3357  1683  1603  1272  326  >95  >95  >95  Yes  12  2588  1255  1290  1006  185  >95  >95  >95  No  14  2206  1064  896  574  240  >95  >95  >95  No  16  1671  945  525  462  95  >95  >95  >95  No  17  730  283  436  340  436  >95  >95  >95  No almost undetectable switched B-cells (Pt1 0.6 %, Pt 14 0.9 %) and poor response to CpG despite the normalization of T-cell counts. B-cell reconstitution was also dependent on the nature of the underlying genetic defect. Pt11, affected by EDA-ID, despite a complete full donor chimerism including T, monocytes and B-cells showed an altered B-cell phenotype and mostly IgM production after CpG stimulation without switched B-cells. Since B-cells derive from healthy transplanted maternal stem and progenitor cells, the absence of memory B-cells is not due to an intrinsic alteration of the Bcells. We hypothesize that developmental abnormalities of the secondary lymphoid organs, caused by the IkBα genetic defect, are responsible for the altered B-cell development and function in vivo [46] . The use of pre-conditioning was generally associated with a better humoral reconstitution with adequate production of immunoglobulins. On the other hand, humoral reconstitution was achieved in 2 patients (ADA-SCID and JAK3) who did not receive pre-conditioning regimen and, despite low proportion of donor B-cell engraftment, showed the presence of normal values of switched B-cell and appropriate in vitro and in vivo B-cell functions. The observation in the ADA-SCID patient (Pt6) is in agreement with the recent retrospective analyses on HCT in ADA-SCID patients showing that humoral immunity was present even after unconditioned transplant [47] . On the other hand, a side by side comparison with a relative of Pt6 who underwent HCT following reduced chemotherapy showed better thymopoiesis and faster B-cell and metabolic reconstitution following conditioning [48] . In the JAK3-deficient (Pt5) patient most B-cells remained of host origin and thus non-functional. In the small fraction of donor B-cells γc-dependent cytokine signaling was intact and the cells were perfectly functional, able to differentiate in switched B-cell and produce immunoglobulin. Indeed, in both patients purified switched memory B-cell were predominant of donor origin indicating a strong selective pressure for normal cells during final stages of B-development. According to our experience, if the method of detecting donor chimerism is not sufficiently sensitive [21] , it could understimate the presence of chimerism in small subsets. Thus, for genetic defects expected to lead to selective advantage, it is important to investigate the percentage of donor-derived B-cells in sorted switched cell subsets. In addition to the underlying genetic disease, the donor source has been an additional factor associated to humoral recovery that is influenced by the use of non-HLA-identical donors. We did not find major difference between MSD and MUD in terms of B-cell recovery kinetic, although the two group are too small to draw definitive conclusions. The worse outcome was detected in 2 patients who underwent transplant from a MMRD and showed persisting low memory B-cell (both IgM memory and switched B-cell), did not respond properly to CpG and needed IgRT. In this regard, the use of alternative methods of T-cell depletion has greatly improved the outcome of MMRD transplant and kinetics of T-cell reconstitution and could provide also enhanced humoral immunity long-term [6] .
Conclusions
B-cell reconstitution remains a significant issue after HCT for PID with important implications. Since the recovery of switched B-cells and their capacity to produce Ig in vitro corresponds to ability to mount an effective antibody response to antigens and to vaccinations, in patients with absent memory B-cells or abnormal functional in vitro tests would be safer postpone the IgRT discontinuation. Even if our cohort is too small to give general reccomandations more thorough analyses of B cell function and distinct B-cell phenotype (IgM memory and switched memory) are recommended. Moreover, due to the delay in IgM memory recovery, the patients could benefit from long-term antibiotic prophylaxis and a careful anti-pneumococcus immunization.
Multicenter studies exploiting standardised methodology seem therefore necessary to better define the determinants of B-cell recovery in different form of PID and allow the development of new algorithms for management and follow-up of these critical children.
